Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Cancer: Breakthrough Pain × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Pain 6 Neoplasms 6 Cancer Pain 6 Pain, Intractable 2 Multiple Myeloma 2 Lymphoma 2 Leukemia, Myeloid, Acute 2 Leukemia, Biphenotypic, Acute 2 Leukemia 2 Waldenstrom Macroglobulinemia 1 Vesico-Ureteral Reflux 1 Ureteral Neoplasms 1 Thrombocythemia, Essential 1 Sezary Syndrome 1 Prostatic Neoplasms 1 Primary Myelofibrosis 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Precancerous Conditions 1 Polycythemia Vera 1 Pdgfra-Associated Chronic Eosinophilic Leukemia 1 Pain, Postoperative 1 Nephrolithiasis 1 Neoplasms, Plasma Cell 1 Myeloproliferative Disorders 1 Myelodysplastic Syndromes 1 Mycosis Fungoides 1 Mucositis 1 Monoclonal Gammopathy of Undetermined Significance 1 Lymphoma, T-Cell, Cutaneous 1

Interventions

Morphine 1 Ketamine 1 Chitosan 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02591017 2018-11-13

ONKEMI

University Hospital, Basel, Switzerland

Phase 3 Terminated

Cancer: Breakthrough Pain

Data powered by HemOnc (CC BY 4.0) Colophon ⚡